Anaplastic Large Cell Lymphoma - Pipeline Insight, 2024

This “Anaplastic Large Cell Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Anaplastic Large Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anaplastic Large Cell Lymphoma Understanding

Anaplastic Large Cell Lymphoma: Overview

Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL), and one of the subtypes of T cell lymphoma. ALCL comprises about one percent of all NHLs and approximately 16 percent of all T cell lymphomas. The hallmark of ALCL is the overexpression of the CD30 cell surface marker, a cytokine receptor belonging to the tumor necrosis factor receptor superfamily. ALCL can be further classified into two main subtypes based on the presence or absence of anaplastic lymphoma kinase (ALK) gene rearrangements: ALK-positive and ALK-negative. In ALK-positive cases, a fusion protein involving ALK is formed, driving uncontrolled cell growth. In ALK-negative cases, alternative molecular mechanisms contribute to the pathogenesis. The interaction between these abnormal lymphocytes and the surrounding microenvironment plays a crucial role in disease progression.

A diagnosis of ALCL requires taking a biopsy (small sample of tumor tissue or abnormal skin tissue) and looking at the cells under a microscope. Additional tests may be conducted to give physicians more information about the disease and how far it has spread in the body. These can include blood tests, a CT scan, a PET scan, a MRI scan, and bone marrow biopsy. ALCL can initially appear either in the skin, the lymph nodes, or in organs throughout the body. ALCL that appears in the skin is most often called primary cutaneous ALCL, and it typically has a less aggressive disease course than the systemic type. The characteristic features of primary cutaneous ALCL include the appearance of solitary or multiple raised, red skin lesions that do not go away, have a tendency to ulcerate, and may itch. Only about 10 percent of the time does primary cutaneous ALCL extend beyond the skin to lymph nodes or organs. If this occurs, it is usually treated like systemic ALCL.

Anaplastic Large Cell Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anaplastic Large Cell Lymphoma pipeline landscape is provided which includes the disease overview and Anaplastic Large Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Anaplastic Large Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anaplastic Large Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic Large Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Anaplastic Large Cell Lymphoma.

Anaplastic Large Cell Lymphoma Emerging Drugs Chapters

This segment of the Anaplastic Large Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anaplastic Large Cell Lymphoma Emerging Drugs

AFM13: Affimed TherapeuticsAFM13 is a type of immunotherapy being developed by Affimed to possibly treat Hodgkin's lymphoma (HL) and some types of non-Hodgkin's lymphoma (NHL). AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. The drug is currently in Phase I/II of clinical development.

AUTO4: Autolus LimitedAUTO4 is a programmed T cell product candidate in clinical development for Anaplastic Large Cell Lymphoma. AUTO4 selectively targets TRBC1 over TRBC2, allowing for elimination of the T-cell malignancy in TRBC1-positive cells and simultaneous preservation of enough normal TRBC2-positive T cells to maintain immunity. The drug is currently in Phase I/II stage of its clinical development.

Anaplastic Large Cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Anaplastic Large Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anaplastic Large Cell Lymphoma

There are approx. 4+ key companies which are developing the therapies for Anaplastic Large Cell Lymphoma. The companies which have their Anaplastic Large Cell Lymphoma drug candidates in the most advanced stage, i.e. phase I/II include, Autolus Limited.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anaplastic Large Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anaplastic Large Cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anaplastic Large Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic Large Cell Lymphoma drugs.

Anaplastic Large Cell Lymphoma Report Insights

• Anaplastic Large Cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anaplastic Large Cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anaplastic Large Cell Lymphoma drugs?
• How many Anaplastic Large Cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anaplastic Large Cell Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anaplastic Large Cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anaplastic Large Cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Affimed Therapeutics
• Autolus Limited
• Chia Tai Tianqing Pharmaceutical Group
• Pfizer

Key Products

• AFM13
• AUTO4
• TQ-B3101
• Lorlatinib

This product will be delivered within 2 business days.